US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRAWS PHARMA

1.52

-0.4500-22.84%

Volume:246.68K

Turnover:374.23K

Market Cap:12.15M

PE:-0.84

High:1.55

Open:1.51

Low:1.51

Close:1.97

52wk High:5.26

52wk Low:0.9700

Shares:7.99M

Float Shares:5.93M

Volume Ratio:127.89

T/O Rate:4.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8200

EPS(LYR):-35.2126

ROE:-1059.63%

ROA:-92.29%

PB:2.67

PE(LYR):-0.04

Loading ...

Overview Company News Filings

BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold

BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients

Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

THOMSON REUTERS

Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind

THOMSON REUTERS

Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16

THOMSON REUTERS

Traws Pharma initiated with a Buy at Ladenburg

Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy

Traws Pharma Inc: Full Study Enrollment Expected in January 2026

THOMSON REUTERS

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients

THOMSON REUTERS

Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients

Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds

THOMSON REUTERS

Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026

THOMSON REUTERS

Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients

THOMSON REUTERS

Traws Pharma Grants Stock Options and RSUs to Executive Team

HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target

MT Newswires Live

Traws Pharma Initiated at Buy by HC Wainwright & Co.

Traws Pharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TRAW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.52,"timestamp":1771511966486,"preClose":1.97,"halted":0,"volume":246679,"delay":0,"changeRate":-0.22842639593908629,"floatShares":5925700,"shares":7990867,"eps":-1.82,"marketStatus":"Trading","change":-0.45,"latestTime":"02-19 09:39:38 EST","open":1.51,"high":1.55,"low":1.505,"amount":374230.0012312,"amplitude":0.022843,"askPrice":1.56,"askSize":200,"bidPrice":1.5,"bidSize":4016,"shortable":0,"etf":0,"ttmEps":-1.82,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.97,"preHourTrading":{"tag":"盘前","latestPrice":1.5291,"preClose":1.97,"latestTime":"09:26 EST","volume":107009,"amount":166146.7426843,"timestamp":1771511207777,"change":-0.4409,"changeRate":-0.223807,"amplitude":0.335025},"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":1.97,"latestTime":"17:32 EST","volume":52,"amount":102.42,"timestamp":1771453920519,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":127.890772,"impliedVol":1.6331,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","floatShares":5925700,"roa":"-92.29%","roe":"-1059.63%","lyrEps":-35.212551,"volumeRatio":127.890772,"shares":7990867,"dividePrice":0,"high":1.55,"amplitude":0.022843,"preClose":1.97,"low":1.505,"week52Low":0.97,"pbRate":"2.67","psRate":"4.27","week52High":5.26,"institutionHeld":0,"latestPrice":1.52,"committee":0.905123,"eps":-1.82,"divideRate":0,"volume":246679,"delay":0,"ttmEps":-1.82,"open":1.51,"prevYearClose":1.13,"prevWeekClose":1.92,"prevMonthClose":2.11,"prevQuarterClose":1.13,"fiveDayClose":1.94,"twentyDayClose":2.43,"sixtyDayClose":2.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TRAW","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.34},{"market":"US","date":"2025-08-14","symbol":"TRAW","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.11},{"market":"US","date":"2025-05-15","symbol":"TRAW","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":2.09},{"market":"US","date":"2025-03-31","symbol":"TRAW","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":95.66},{"market":"US","date":"2024-11-14","symbol":"TRAW","fiscalQuarterEnding":"2024/09","expectedEps":-6.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-8.81}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAW\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1765170000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAW","date":"2026-02-17","current":-1.082418,"percent":0.091314,"low":-1.693158,"twenty":-0.80456,"median":-0.158601,"eighty":-0.064364,"high":-0.033516,"avg":-0.443731,"sd":0.441667,"marketCap":15342464},"quantilePoints":[{"date":"2024-04-05","current":-0.930105,"twenty":-0.930105,"median":-0.930105,"eighty":-0.930105,"marketCap":17623624},{"date":"2024-04-12","current":-0.875242,"twenty":-0.899279,"median":-0.879971,"eighty":-0.87246,"marketCap":16584087},{"date":"2024-04-19","current":-0.774197,"twenty":-0.884701,"median":-0.859217,"eighty":-0.774642,"marketCap":14669484},{"date":"2024-04-26","current":-0.703922,"twenty":-0.875242,"median":-0.784323,"eighty":-0.745597,"marketCap":13337908},{"date":"2024-05-03","current":-0.713993,"twenty":-0.87246,"median":-0.75973,"eighty":-0.713993,"marketCap":13528735},{"date":"2024-05-10","current":-0.722239,"twenty":-0.859217,"median":-0.743093,"eighty":-0.71377,"marketCap":13684982},{"date":"2024-05-17","current":-0.7463,"twenty":-0.799236,"median":-0.738475,"eighty":-0.713993,"marketCap":13549821},{"date":"2024-05-24","current":-0.73457,"twenty":-0.794005,"median":-0.741761,"eighty":-0.718444,"marketCap":13336853},{"date":"2024-05-31","current":-0.675921,"twenty":-0.778515,"median":-0.736522,"eighty":-0.713681,"marketCap":12272014},{"date":"2024-06-07","current":-0.836261,"twenty":-0.794624,"median":-0.73457,"eighty":-0.711322,"marketCap":15183160},{"date":"2024-06-14","current":-0.873049,"twenty":-0.83888,"median":-0.740589,"eighty":-0.71288,"marketCap":15851082},{"date":"2024-06-21","current":-0.649387,"twenty":-0.836845,"median":-0.738475,"eighty":-0.709541,"marketCap":11790270},{"date":"2024-06-28","current":-0.62709,"twenty":-0.83835,"median":-0.738475,"eighty":-0.706993,"marketCap":11385454},{"date":"2024-07-05","current":-0.557395,"twenty":-0.836651,"median":-0.734469,"eighty":-0.698614,"marketCap":10120072},{"date":"2024-07-12","current":-0.483661,"twenty":-0.814046,"median":-0.728873,"eighty":-0.672205,"marketCap":8781358},{"date":"2024-07-15","current":-0.554747,"twenty":-0.806641,"median":-0.726171,"eighty":-0.663181,"marketCap":10071990},{"date":"2024-08-02","current":-0.532446,"twenty":-0.799236,"median":-0.724978,"eighty":-0.649387,"marketCap":9667086},{"date":"2024-08-09","current":-0.491259,"twenty":-0.797102,"median":-0.722239,"eighty":-0.600613,"marketCap":8919304},{"date":"2024-08-16","current":-0.066488,"twenty":-0.794005,"median":-0.718444,"eighty":-0.532446,"marketCap":9112137},{"date":"2024-08-23","current":-0.065565,"twenty":-0.774642,"median":-0.71377,"eighty":-0.508851,"marketCap":8985580},{"date":"2024-08-30","current":-0.06743,"twenty":-0.774197,"median":-0.709986,"eighty":-0.494812,"marketCap":9241226},{"date":"2024-09-06","current":-0.06538,"twenty":-0.762623,"median":-0.702951,"eighty":-0.490604,"marketCap":8960268},{"date":"2024-09-13","current":-0.062794,"twenty":-0.758648,"median":-0.694503,"eighty":-0.071087,"marketCap":8605907},{"date":"2024-09-20","current":-0.057254,"twenty":-0.751084,"median":-0.683063,"eighty":-0.068232,"marketCap":7846562},{"date":"2024-09-27","current":-0.081301,"twenty":-0.74722,"median":-0.649387,"eighty":-0.067774,"marketCap":11142278},{"date":"2024-10-04","current":-0.073971,"twenty":-0.746382,"median":-0.624791,"eighty":-0.068232,"marketCap":10137646},{"date":"2024-10-11","current":-0.065174,"twenty":-0.745738,"median":-0.557395,"eighty":-0.067596,"marketCap":8932088},{"date":"2024-10-18","current":-0.062642,"twenty":-0.744673,"median":-0.543597,"eighty":-0.067316,"marketCap":8585034},{"date":"2024-10-25","current":-0.111702,"twenty":-0.743234,"median":-0.515682,"eighty":-0.066488,"marketCap":15308680},{"date":"2024-10-31","current":-0.109715,"twenty":-0.741526,"median":-0.508851,"eighty":-0.066652,"marketCap":15036392},{"date":"2024-11-08","current":-0.111592,"twenty":-0.739321,"median":-0.498158,"eighty":-0.06682,"marketCap":15293553},{"date":"2024-11-15","current":-0.123204,"twenty":-0.736132,"median":-0.492107,"eighty":-0.067201,"marketCap":16884930},{"date":"2024-11-22","current":-0.096923,"twenty":-0.734509,"median":-0.489621,"eighty":-0.06743,"marketCap":13645248},{"date":"2024-11-29","current":-0.098427,"twenty":-0.734469,"median":-0.48099,"eighty":-0.067496,"marketCap":13857037},{"date":"2024-12-06","current":-0.108407,"twenty":-0.733312,"median":-0.130241,"eighty":-0.067596,"marketCap":15262104},{"date":"2024-12-13","current":-0.104014,"twenty":-0.729414,"median":-0.121316,"eighty":-0.067685,"marketCap":14643681},{"date":"2024-12-20","current":-0.114642,"twenty":-0.725217,"median":-0.114642,"eighty":-0.068025,"marketCap":16139817},{"date":"2024-12-27","current":-0.244993,"twenty":-0.723719,"median":-0.117501,"eighty":-0.068353,"marketCap":34491315},{"date":"2025-01-03","current":-0.186323,"twenty":-0.723452,"median":-0.123204,"eighty":-0.068427,"marketCap":26231553},{"date":"2025-01-10","current":-0.173429,"twenty":-0.722482,"median":-0.130241,"eighty":-0.069344,"marketCap":24416220},{"date":"2025-01-17","current":-0.146996,"twenty":-0.721141,"median":-0.147157,"eighty":-0.069786,"marketCap":20694789},{"date":"2025-01-24","current":-0.13797,"twenty":-0.719413,"median":-0.140763,"eighty":-0.070056,"marketCap":19424056},{"date":"2025-01-31","current":-0.156666,"twenty":-0.718444,"median":-0.146996,"eighty":-0.070643,"marketCap":22056288},{"date":"2025-02-07","current":-0.178157,"twenty":-0.715773,"median":-0.153981,"eighty":-0.07105,"marketCap":25081842},{"date":"2025-02-14","current":-0.173739,"twenty":-0.713859,"median":-0.157526,"eighty":-0.072709,"marketCap":24459897},{"date":"2025-02-21","current":-0.121618,"twenty":-0.713592,"median":-0.156666,"eighty":-0.073848,"marketCap":17121928},{"date":"2025-02-28","current":-0.087129,"twenty":-0.71288,"median":-0.149414,"eighty":-0.074131,"marketCap":12266456},{"date":"2025-03-07","current":-0.070533,"twenty":-0.710432,"median":-0.144632,"eighty":-0.071013,"marketCap":9929988},{"date":"2025-03-14","current":-0.07157,"twenty":-0.706225,"median":-0.135069,"eighty":-0.071013,"marketCap":10076017},{"date":"2025-03-21","current":-0.074682,"twenty":-0.703145,"median":-0.130241,"eighty":-0.070984,"marketCap":10514105},{"date":"2025-03-28","current":-0.066643,"twenty":-0.70173,"median":-0.123448,"eighty":-0.070533,"marketCap":9382378},{"date":"2025-04-04","current":-0.066422,"twenty":-0.698614,"median":-0.121618,"eighty":-0.069679,"marketCap":11060862},{"date":"2025-04-11","current":-0.053321,"twenty":-0.692996,"median":-0.117957,"eighty":-0.068372,"marketCap":8879132},{"date":"2025-04-17","current":-0.060633,"twenty":-0.690629,"median":-0.115407,"eighty":-0.067596,"marketCap":10096842},{"date":"2025-04-25","current":-0.046618,"twenty":-0.687348,"median":-0.111751,"eighty":-0.066971,"marketCap":7762898},{"date":"2025-05-02","current":-0.042961,"twenty":-0.674063,"median":-0.111618,"eighty":-0.066488,"marketCap":7154043},{"date":"2025-05-09","current":-0.042657,"twenty":-0.663181,"median":-0.111481,"eighty":-0.065417,"marketCap":7103306},{"date":"2025-05-16","current":-0.033516,"twenty":-0.647743,"median":-0.11053,"eighty":-0.064788,"marketCap":5581169},{"date":"2025-05-23","current":-0.045648,"twenty":-0.63835,"median":-0.110157,"eighty":-0.064588,"marketCap":6392975},{"date":"2025-05-30","current":-0.055226,"twenty":-0.62709,"median":-0.109384,"eighty":-0.063348,"marketCap":7734397},{"date":"2025-06-06","current":-0.058802,"twenty":-0.622492,"median":-0.108696,"eighty":-0.062794,"marketCap":8235186},{"date":"2025-06-13","current":-0.071516,"twenty":-0.600613,"median":-0.107668,"eighty":-0.063175,"marketCap":10015767},{"date":"2025-06-20","current":-0.065556,"twenty":-0.566039,"median":-0.107023,"eighty":-0.063313,"marketCap":9181119},{"date":"2025-06-27","current":-0.056815,"twenty":-0.557298,"median":-0.10387,"eighty":-0.062794,"marketCap":7956970},{"date":"2025-07-03","current":-0.05761,"twenty":-0.555758,"median":-0.101756,"eighty":-0.062399,"marketCap":8068256},{"date":"2025-07-11","current":-0.062378,"twenty":-0.541366,"median":-0.099933,"eighty":-0.061976,"marketCap":8735974},{"date":"2025-07-18","current":-0.064364,"twenty":-0.529937,"median":-0.097675,"eighty":-0.061583,"marketCap":9014190},{"date":"2025-07-25","current":-0.064761,"twenty":-0.520715,"median":-0.095947,"eighty":-0.061819,"marketCap":9069833},{"date":"2025-08-01","current":-0.061186,"twenty":-0.513446,"median":-0.092228,"eighty":-0.061583,"marketCap":8569045},{"date":"2025-08-08","current":-0.058802,"twenty":-0.510093,"median":-0.087897,"eighty":-0.061164,"marketCap":8235186},{"date":"2025-08-15","current":-0.50579,"twenty":-0.507369,"median":-0.086481,"eighty":-0.061164,"marketCap":9014190},{"date":"2025-08-22","current":-0.546969,"twenty":-0.527596,"median":-0.090759,"eighty":-0.061186,"marketCap":9748084},{"date":"2025-08-29","current":-0.562823,"twenty":-0.55008,"median":-0.094773,"eighty":-0.061424,"marketCap":10030637},{"date":"2025-09-05","current":-0.65993,"twenty":-0.557347,"median":-0.096218,"eighty":-0.061583,"marketCap":11761275},{"date":"2025-09-12","current":-0.717402,"twenty":-0.561238,"median":-0.098427,"eighty":-0.061583,"marketCap":12785530},{"date":"2025-09-19","current":-0.81649,"twenty":-0.587397,"median":-0.100444,"eighty":-0.06174,"marketCap":14551487},{"date":"2025-09-26","current":-0.745146,"twenty":-0.633715,"median":-0.10251,"eighty":-0.061976,"marketCap":13279998},{"date":"2025-10-03","current":-0.721365,"twenty":-0.66395,"median":-0.104979,"eighty":-0.061978,"marketCap":12856168},{"date":"2025-10-10","current":-1.240589,"twenty":-0.692996,"median":-0.107234,"eighty":-0.06201,"marketCap":22109784},{"date":"2025-10-17","current":-1.058266,"twenty":-0.706225,"median":-0.108145,"eighty":-0.062128,"marketCap":18860423},{"date":"2025-10-24","current":-1.051562,"twenty":-0.713592,"median":-0.109053,"eighty":-0.062292,"marketCap":18740938},{"date":"2025-10-31","current":-1.05556,"twenty":-0.718444,"median":-0.109936,"eighty":-0.06243,"marketCap":18812196},{"date":"2025-11-07","current":-0.809663,"twenty":-0.722967,"median":-0.110382,"eighty":-0.062562,"marketCap":14429809},{"date":"2025-11-14","current":-0.707705,"twenty":-0.726854,"median":-0.111401,"eighty":-0.062695,"marketCap":12612722},{"date":"2025-11-21","current":-1.284879,"twenty":-0.733984,"median":-0.111592,"eighty":-0.062775,"marketCap":17100455},{"date":"2025-11-28","current":-1.621109,"twenty":-0.736689,"median":-0.111702,"eighty":-0.062779,"marketCap":21575340},{"date":"2025-12-05","current":-1.416969,"twenty":-0.741064,"median":-0.113304,"eighty":-0.062794,"marketCap":18858446},{"date":"2025-12-12","current":-1.398957,"twenty":-0.745146,"median":-0.117501,"eighty":-0.062794,"marketCap":18618720},{"date":"2025-12-19","current":-0.750513,"twenty":-0.74863,"median":-0.120524,"eighty":-0.06287,"marketCap":9988583},{"date":"2025-12-26","current":-0.744509,"twenty":-0.74911,"median":-0.123065,"eighty":-0.063175,"marketCap":9908675},{"date":"2026-01-02","current":-0.678464,"twenty":-0.74911,"median":-0.12421,"eighty":-0.063313,"marketCap":9029679},{"date":"2026-01-09","current":-0.846579,"twenty":-0.755955,"median":-0.131212,"eighty":-0.063525,"marketCap":11267122},{"date":"2026-01-16","current":-1.032707,"twenty":-0.760288,"median":-0.140763,"eighty":-0.063894,"marketCap":13744291},{"date":"2026-01-23","current":-1.495023,"twenty":-0.77433,"median":-0.145814,"eighty":-0.063975,"marketCap":19897258},{"date":"2026-01-30","current":-1.260863,"twenty":-0.780019,"median":-0.151509,"eighty":-0.064208,"marketCap":16780820},{"date":"2026-02-06","current":-1.032707,"twenty":-0.795244,"median":-0.157096,"eighty":-0.064364,"marketCap":13744291},{"date":"2026-02-13","current":-1.152789,"twenty":-0.80455,"median":-0.158601,"eighty":-0.064364,"marketCap":15342464},{"date":"2026-02-17","current":-1.152789,"twenty":-0.80456,"median":-0.158601,"eighty":-0.064364,"marketCap":15342464}],"updateTime":1771491429339},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612400625","title":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400625","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400625?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:17","pubTimestamp":1771507073,"startTime":"0","endTime":"0","summary":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold** Shares of Traws Pharma TRAW.O down 20.81% at $1.58 premarket** Co says the U.S. FDA placed on clinical hold its investigational new drug application for tivoxavir marboxil, a single oral tablet for prevention of seasonal influenza** Adds that FDA flagged concerns \"with the mutagenicity data package\" for drug in application** Also says it filed the application to allow the government's biomedical research unit to fully review its bid for inclusion in the strategic stockpile for avianflu treatment** Clinical hold does not directly impact ongoing and planned studies outside of the United States; working to mitigate issue in clinical development plan - TRAW  ** TRAW shares up 74.3% YTD       ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2612140749","title":"BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612140749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612140749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:58","pubTimestamp":1771505921,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid-Eligible And Ineligible Covid-19 Patients Feb 19 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA COMPLETES ANALYSIS OF ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2612059402","title":"Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612059402","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612059402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504217,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. reported completion of its clinical analysis from a 90-patient, open-label Phase 2 study evaluating ratutrelvir, an investigational oral ritonavir-free Mpro/3CL protease inhibitor, versus PAXLOVID in mild-to-moderate COVID-19 patients, including a separate single-arm cohort of PAXLOVID-ineligible patients. The company said the analysis found fewer treatment-related adverse events and no viral rebound events in ratutrelvir-treated patients, with equivalent time to sustained symptom resolution versus PAXLOVID; in PAXLOVID-ineligible patients, it reported a shorter time to symptom resolution compared with PAXLOVID. The company also provided preclinical and development updates on tivoxavir marboxil tablets for once-monthly influenza prophylaxis, including plans for a PK study under an open IND in Australia and preparations for a human influenza prophylaxis challenge study in the UK. The ratutrelvir results were presented as completed in the announcement; no future present","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL41fzpr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4112","IE00BKPKM429.USD","LU2210150020.SGD","BK4007","SG9999014039.USD","SG9999014005.SGD","NDAQ","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2612540274","title":"Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza","url":"https://stock-news.laohu8.com/highlight/detail?id=2612540274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612540274?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2612402749","title":"Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2612402749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612402749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2612060402","title":"Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2612060402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612060402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2607010262","title":"Traws Pharma initiated with a Buy at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2607010262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607010262?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:20","pubTimestamp":1769775623,"startTime":"0","endTime":"0","summary":"Ladenburg initiated coverage of Traws Pharma (TRAW) with a Buy rating and $6.50 price target The firm says the company offers an alternative to Cid...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-initiated-with-a-buy-at-ladenburg-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-initiated-with-a-buy-at-ladenburg-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2606439412","title":"Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2606439412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606439412?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:30","pubTimestamp":1769434251,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. announced the completion of enrollment in its Phase 2 clinical study evaluating ratutrelvir, an investigational oral Mpro/3CL protease inhibitor, in comparison to PAXLOVID in patients with mild-to-moderate COVID-19. The study also includes a single arm for patients ineligible to receive PAXLOVID. According to the company, ongoing clinical results indicate ratutrelvir has demonstrated a differentiated profile versus PAXLOVID, with observations of fewer adverse events, absence of viral rebounds, and faster time to sustained symptom resolution. These findings have also been observed in PAXLOVID-ineligible patients. Final results have not yet been presented. Additionally, Traws Pharma provided an update on its tivoxavir marboxil program, indicating that a new compressed tablet formulation may offer 28-day prophylactic protection against a broad range of seasonal and pandemic-potential influenza variants. A human influenza prophylaxis challenge study is scheduled for June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL5jKGpq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","TRAW","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4007","BK4112"],"gpt_icon":0},{"id":"2606024346","title":"Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza","url":"https://stock-news.laohu8.com/highlight/detail?id=2606024346","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606024346?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:30","pubTimestamp":1769434200,"startTime":"0","endTime":"0","summary":"Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/26/3225645/0/en/Traws-Pharma-Completes-Enrollment-of-Ratutrelvir-Clinical-Study-in-PAXLOVID-Eligible-and-Ineligible-COVID-19-Patients-Announces-Plans-for-Added-Indication-for-Tivoxavir-Marboxil-as.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","BK4139","PK","BK4007","BK4548","BK4568","BNTX","BK4588","TRAW","BK4535","BK4551","BK4585"],"gpt_icon":0},{"id":"2603686627","title":"Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686627","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686627?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305620,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has filed an Investigational New Drug  application with the U.S. Food and Drug Administration  for tivoxavir marboxil , an oral CAP-dependent endonuclease inhibitor intended for the treatment of influenza. The filing marks a key step towards formal consideration by the FDA and the Center for the Biomedical Advanced Research and Development Authority  for potential inclusion of TXM in the U.S. strategic national stockpile. No grant or funding involving multiple organizations was mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL7pplcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","TRAW","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2603863946","title":"Traws Pharma Inc: Full Study Enrollment Expected in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603863946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603863946?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8WSL4L:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2603686345","title":"Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686345?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8WSL4L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2592399184","title":"Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399184","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592399184?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969221,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via Glob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL38GghF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014021.USD","BK4007","LU0314104364.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","TRAW","LU2095319765.USD","BK4588","SG9999014013.SGD","NDAQ"],"gpt_icon":0},{"id":"2592991829","title":"Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991829?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2592991823","title":"Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991823?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2592918579","title":"Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918579?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2592958804","title":"Traws Pharma Grants Stock Options and RSUs to Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2592958804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592958804?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:01","pubTimestamp":1765922477,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units  under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1wrvY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2588304501","title":"HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2588304501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588304501?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:39","pubTimestamp":1764765553,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2588045364","title":"Traws Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045364?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:10","pubTimestamp":1764763800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRAW/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 07:10 ET (12:10 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2588101075","title":"Traws Pharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2588101075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588101075?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:02","pubTimestamp":1764759763,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nAZN4R6ELH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}